Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients.
The dystrophin deficiency leading to the severely progressing muscle degeneration in Duchenne muscular dystrophy (DMD) patients is caused by frame-shifting mutations in the DMD gene. We are developing a reading frame correction therapy aimed at the antisense-induced skipping of targeted exons from the pre-mRNA. Despite introducing a (larger) deletion, an in-frame transcript is generated that allows the synthesis of a slightly shorter, but largely functional dystrophin as found in the mostly milder Becker muscular dystrophy (BMD). We have recently demonstrated both the efficacy and high efficiency of the antisense-induced skipping of numerous exons from the DMD transcript in control muscle cells. In principle, this would restore the reading frame in over 75% of the patients reported in the Leiden DMD mutation database. In this study, we in fact demonstrate the broad therapeutic applicability of this strategy in cultured muscle cells from six DMD patients carrying different deletions and a nonsense mutation. In each case, the specific skipping of the targeted exon was induced, restoring dystrophin synthesis in over 75% of cells. The protein was detectable as soon as 16 h post-transfection, then increased to significant levels at the membrane within 2 days, and was maintained for at least a week. Finally, its proper function was further suggested by the restored membranal expression of four associated proteins from the dystrophin-glycoprotein complex. These results document important progress towards a clinically applicable, small-molecule based therapy.
Aartsma-Rus
Annemieke
A
Center for Human and Clinical Genetics, Leiden University Medical Center, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands.
Janson
Anneke A M
AA
Kaman
Wendy E
WE
Bremmer-Bout
Mattie
M
den Dunnen
Johan T
JT
Baas
Frank
F
van Ommen
Gert-Jan B
GJ
van Deutekom
Judith C T
JC
D015153:Blotting, Western; D002478:Cells, Cultured; D016189:Dystrophin / Q000235:genetics*; D005091:Exons; D006801:Humans; D007150:Immunohistochemistry; D032342:Muscle Cells; D020388:Muscular Dystrophy, Duchenne / Q000235:genetics / Q000628:therapy*; D009154:Mutation; D020320:Oligoribonucleotides, Antisense / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
D016189:Dystrophin; D020320:Oligoribonucleotides, Antisense